{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+A&page=17",
    "query": {
      "intervention": "Part A",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 8722,
    "total_pages": 873,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+A&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+A&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T20:52:33.371Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04002115",
      "title": "Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI)",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Granulocyte Colony-Stimulating Factor",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Cellcept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-06-03",
      "completion_date": "2022-11-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-14",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04002115"
    },
    {
      "nct_id": "NCT04509115",
      "title": "Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Opioid Use",
        "Opioid Prescribing"
      ],
      "interventions": [
        {
          "name": "Short-acting opioid prescription for acute pain",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1709,
      "start_date": "2020-09-11",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2023-12-05",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04509115"
    },
    {
      "nct_id": "NCT03850535",
      "title": "A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Idasanutlin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-03-25",
      "completion_date": "2020-09-10",
      "has_results": true,
      "last_update_posted_date": "2022-06-21",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03850535"
    },
    {
      "nct_id": "NCT04171895",
      "title": "Communication Training for Caregivers In Advanced Care Planning",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Malignant Brain Tumors",
        "Advanced Care Planning"
      ],
      "interventions": [
        {
          "name": "Questionnaires",
          "type": "OTHER"
        },
        {
          "name": "Communication training Part 1 (no longer recruiting)",
          "type": "OTHER"
        },
        {
          "name": "Enhanced usual care",
          "type": "OTHER"
        },
        {
          "name": "Communication training Part II",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2019-11-19",
      "completion_date": "2024-08-22",
      "has_results": false,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04171895"
    },
    {
      "nct_id": "NCT06530030",
      "title": "Goal Attainment and Physical Activity in People With Hemophilia A",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "efanesoctocog alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 3,
      "start_date": "2024-11-26",
      "completion_date": "2025-09-18",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 1,
      "location_summary": "Peoria, Illinois",
      "locations": [
        {
          "city": "Peoria",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06530030"
    },
    {
      "nct_id": "NCT04843228",
      "title": "Cognitive Bias Modification for Perfectionism and Intolerance to Uncertainty",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Perfectionism",
        "Intolerance to Uncertainty"
      ],
      "interventions": [
        {
          "name": "Cognitive Bias Modification",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Cognitive Bias Modification for Control Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Istanbul Sabahattin Zaim University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2021-03-01",
      "completion_date": "2021-07-15",
      "has_results": false,
      "last_update_posted_date": "2022-08-26",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 1,
      "location_summary": "Lowell, Massachusetts",
      "locations": [
        {
          "city": "Lowell",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843228"
    },
    {
      "nct_id": "NCT06611436",
      "title": "BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hemophilia B",
        "Hemophilia B, Moderately Severe or Severe"
      ],
      "interventions": [
        {
          "name": "BE-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Be Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 5,
      "start_date": "2024-12-04",
      "completion_date": "2026-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 5,
      "location_summary": "Davis, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06611436"
    },
    {
      "nct_id": "NCT05938036",
      "title": "Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Respiratory Distress Syndrome (ARDS)"
      ],
      "interventions": [
        {
          "name": "ALT-100 mAb",
          "type": "DRUG"
        },
        {
          "name": "ALT-100 (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aqualung Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 15,
      "start_date": "2023-12-01",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-23",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05938036"
    },
    {
      "nct_id": "NCT04304144",
      "title": "A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AL Amyloidosis"
      ],
      "interventions": [
        {
          "name": "CAEL-101",
          "type": "DRUG"
        },
        {
          "name": "SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)",
          "type": "DRUG"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2020-03-18",
      "completion_date": "2023-11-14",
      "has_results": true,
      "last_update_posted_date": "2025-03-05",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 3,
      "location_summary": "Stanford, California • Detroit, Michigan • Cleveland, Ohio",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04304144"
    },
    {
      "nct_id": "NCT06305234",
      "title": "A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Phenylketonuria (PKU)"
      ],
      "interventions": [
        {
          "name": "Pegvaliase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 200,
      "start_date": "2024-01-20",
      "completion_date": "2033-11-18",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-20T20:52:33.371Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305234"
    }
  ]
}